We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00694278
Recruitment Status : Unknown
Verified June 2008 by Ferzli, George S., M.D. F.A.C.S..
Recruitment status was:  Recruiting
First Posted : June 10, 2008
Last Update Posted : June 10, 2008
Information provided by:

Study Description
Brief Summary:
The aim of this study and the primary outcome is to clinically evaluate effect of laparoscopic duodenal-jejunal bypass on non-obese type 2 diabetes. Secondary outcomes will evaluate CCK, FFA, Cholesterol Ghrelin, C-peptide, and HbA1c levels. Patients will be followed closely to ensure the desired results are sustained in long term

Condition or disease Phase
Type II Diabetes Early Phase 1

Study Design

Study Type : Observational
Estimated Enrollment : 15 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes in Adults
Study Start Date : June 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
primary care office

Inclusion Criteria:

  • Adults age 20-65 years
  • Clinical diagnosis of type II diabetes buy on of the following three criteria (American Diabetes Association)

    1. A normal or high C-peptide level (to exclude type 1 diabetes) (>.9ng/ml)
    2. A random plasma glucose of 200mg/dl or more with typical symptom of diabetes
    3. A fasting plasma glucose of 126mg/dl or more on more than one occasion
  • BMI 22-34 KG/m2
  • Patients on oral hypoglycemic medications or insulin to control T2DM
  • Inadequate control of diabetes as defined as HbA1c>7.5
  • No contraindication for surgery or General Anesthesia as determined by multidisciplinary surgical team
  • Ability to understand and describe the mechanism of action of ricks and benefits of the operation

Exclusion Criteria:

  • Patients who meet any of the following exclusion criteria will be exclusion criteria will be excluded from enrollment into the study
  • Enrolled in another clinical study which involves and investigational drug
  • Diagnosis type 1 diabetes
  • Pregnancy (all female patients will have beta HCG) or planned pregnancy within 2 years of entry into the study or unwilling to use reliable contraceptive method
  • Previous gastric or esophageal surgery
  • Immunosuppressive drugs including corticosteroids
  • Coagulopathy (INR>1.5 or platelets<50,000/ul)
  • Anemia (Hgb<10.0g/dl)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00694278

Contact: George Ferzli, MD 718-630-7351 gferzli@lmcmc.com

United States, New York
Lutheran Medical Center Recruiting
Brooklyn, New York, United States, 11220
Contact: George Ferzli, MD    718-630-7351      
Sponsors and Collaborators
Ferzli, George S., M.D. F.A.C.S.
Study Chair: George Ferzli, MD Lutheran Medical Center
More Information

Responsible Party: Georger Ferzli M.D F.A.C.S., Lutheran Medical Center
ClinicalTrials.gov Identifier: NCT00694278     History of Changes
Other Study ID Numbers: LMC95
First Posted: June 10, 2008    Key Record Dates
Last Update Posted: June 10, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases